Abstract #3132

Comparisons of the Efficacy of the Jak1/2 Inhibitor AZD1480 with the VEGF Signaling Inhibitor Cediranib (AZD2171) & Sham Treatments in Mouse Tumors using DCE-MRI, DW-MRI, & Histology

Mary E. Loveless^1,2, Deborah Lawson³, Michael Collins³, Deborah Morosini³, Corinne Reimer³, Dennis Huszar³, Jane Halliday⁴, John C. Waterton⁴, John C. Gore^2,5, Thomas E. Yankeelov^2,5

¹Biomedical Engineering, Vanderbilt University, Nashville, TN, United States; ²Institute of Imaging Science, Vanderbilt University, Nashville, TN, United States; ³Cancer Bioscience, AstraZeneca, Boston, MA, United States; ⁴Translational Sciences: Imaging, AstraZeneca, Macclesfield, Cheshire, United Kingdom; ⁵Radiology & Radiological Science, Vanderbilt University, Nashville, TN, United States

AZD1480 is a novel small molecule inhibitor of Jak 1/2, which have been shown to be key mediators of Stat3 activation. Both DW-MRI and DCE-MRI have been widely used previously to monitor cancer treatment. Jak/Stat pathway inhibition has been shown to modulate tumor cell survival and tumor angiogenesis, so this work seeks to assess the utility of DW-MRI and DCE-MRI in assessing the efficacy of AZD1480 compared to the anti-angiogenic drug cediranib at early treatment time points. The results fo this study indicate that DW-MRI is more sensitive to the effects of AZD 1480 treatment compared to DCE-MRI measurements.